TTRX Latest Press Releases

-- November 9, 2026 --

Turn Therapeutics Provides Corporate Updates and Reports Third Quarter 2026 Financial Results Business Wire 7:00 AM

-- November 5, 2026 --

Turn Therapeutics' GX-03 Earns 'Developmental Immunology Solution of the Year' in 2026 BioTech Breakthrough Awards Program Business Wire 8:00 AM

-- October 21, 2026 --

U.S. Bancorp | BTIG to Host Turn Therapeutics for Virtual Fireside Chat Business Wire 4:01 PM

-- September 10, 2026 --

Turn Therapeutics to Present at Stifel 2026 Virtual Immunology and Inflammation Forum Business Wire 8:00 AM

-- September 9, 2026 --

Turn Therapeutics Appoints Former CDC Director Robert R. Redfield, M.D., as Chief Scientific Officer Business Wire 8:00 AM

-- September 8, 2026 --

NovaBridge Appoints Martin Dewhurst to Board of Directors as an Independent Director Globe Newswire 7:00 AM

-- August 20, 2026 --

Turn Therapeutics Announces New Peer-Reviewed Research Showing GX-03 Selectively Reduces Key Drivers of Skin Inflammation and Itch Business Wire 8:00 AM

-- August 12, 2026 --

Turn Therapeutics Provides Corporate Updates and Reports Second Quarter 2026 Financial Results Business Wire 4:30 PM

-- July 28, 2026 --

Turn Therapeutics to Ring the Nasdaq Closing Bell on Monday, August 10, 2026 Business Wire 8:01 AM

-- July 7, 2026 --

Turn Therapeutics Announces Final Stage 2 Design and Data-Driven Expansion of GX-03 Phase 2 Program in Atopic Dermatitis Business Wire 8:05 AM

-- July 6, 2026 --

Turn Therapeutics to Host Webcast Presenting Comprehensive Interim Analysis and Optimized Stage 2 Design for GX-03 in Atopic Dermatitis Business Wire 4:01 PM

Market Data Delayed 15 Minutes